Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis
| العنوان: | Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis |
|---|---|
| المؤلفون: | José Luis Muñoz-Blanco, Adrián Galiana, Pilar Zaragoza, Laura Moreno, Lucía Galán, Marina Mora, Claudia Tarlarini, Paz Torre Merino, Miguel A. Martín, Juan M. Cano, Silvana Penco, Larrodé P, Pilar Cordero Vázquez, Juan F. Roy, Alexandra Juárez Rufián, Elena Pegoraro, María Jesús Muñoz, Gianni Sorarù, Jesús Mora, Gabriela Atencia Cibreiro, Ana C. Calvo, Christian Lunetta, Rosario Osta, Alberto Garcia Redondo, Jesús Esteban |
| المصدر: | Aging and Disease Zaguán. Repositorio Digital de la Universidad de Zaragoza instname |
| بيانات النشر: | Aging and Disease, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, Longitudinal study, Prognostic biomarker, Alpha (ethology), Disease, Pathology and Forensic Medicine, ALS, Collagen XIX type A1, Disease progression, Neurodegeneration, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Amyotrophic lateral sclerosis, Muscle biopsy, medicine.diagnostic_test, business.industry, Cell Biology, medicine.disease, Clinical trial, 030104 developmental biology, Cohort, Original Article, Neurology (clinical), Geriatrics and Gerontology, business, 030217 neurology & neurosurgery |
| الوصف: | The identification of more reliable diagnostic or prognostic biomarkers in age-related neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), is urgently needed. The objective in this study was to identify more reliable prognostic biomarkers of ALS mirroring neurodegeneration that could be of help in clinical trials. A total of 268 participants from three cohorts were included in this study. The muscle and blood cohorts were analyzed in two cross-sectional studies, while the serial blood cohort was analyzed in a longitudinal study at 6-monthly intervals. Fifteen target genes and fourteen proteins involved in muscle physiology and differentiation, metabolic processes and neuromuscular junction dismantlement were studied in the three cohorts. In the muscle biopsy cohort, the risk for a higher mortality in an ALS patient that showed high Collagen type XIX, alpha 1 (COL19A1) protein levels and a fast progression of the disease was 70.5% (P < 0.05), while in the blood cohort, this risk was 20% (P < 0.01). In the serial blood cohort, the linear mixed model analysis showed a significant association between increasing COL19A1 gene levels along disease progression and a faster progression during the follow-up period of 24 months (P < 0.05). Additionally, higher COL19A1 levels and a faster progression increased 17.9% the mortality risk (P < 0.01). We provide new evidence that COL19A1 can be considered a prognostic biomarker that could help the selection of homogeneous groups of patients for upcoming clinical trial and may be pointed out as a promising therapeutic target in ALS. |
| وصف الملف: | application/pdf |
| تدمد: | 2152-5250 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e108735d223c19dd8301f4c3da644fTest https://doi.org/10.14336/ad.2018.0917Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....81e108735d223c19dd8301f4c3da644f |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21525250 |
|---|